Skip to main content
GenSight Biologics S.A. logo

GenSight Biologics S.A. — Investor Relations & Filings

Ticker · SIGHT ISIN · FR0013183985 LEI · 549300NK4AB8OUEX1F54 PA Manufacturing
Open in API
Filings indexed 628 across all filing types
Latest filing 2026-05-29 Major Shareholding Noti…
Country FR France
Listing PA SIGHT

About GenSight Biologics S.A.

https://www.gensight-biologics.com

GenSight Biologics is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative gene therapies for patients with neurodegenerative retinal diseases and disorders of the central nervous system. The company's therapeutic approach is based on two core technology platforms: the Mitochondrial Targeting Sequence (MTS) and optogenetics. Its lead product candidate, LUMEVOQ (lenadogene nolparvovec), is a gene therapy in late-stage clinical development for treating vision loss from rare mitochondrial diseases. The company's pipeline also includes GS030, an optogenetic-based therapy in clinical trials for retinal degenerative diseases.

Recent filings

Filing Released Lang Actions
Franchissement de seuils
Major Shareholding Notification Classification · 90% confidence The document is a French AMF filing titled “Déclaration de franchissement de seuils (article L. 233-7 du code de commerce)” which reports that a shareholder has crossed below the 5% threshold of share capital and voting rights. It provides details on the number of shares and convertible instruments held and cites the relevant regulatory article for threshold notifications. This is clearly a major shareholding notification regarding crossing of ownership thresholds.
2026-05-29 French
Inside Information / Other news releases
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document is a press release announcing the outcomes of shareholders’ votes at the Combined General Meeting held on May 19, 2026. It lists the approved resolutions and refers to the vote results, fitting the definition of a Declaration of Voting Results & Voting Rights Announcement.
2026-05-20 English
Informations privilégiées / Autres communiqués
Declaration of Voting Results & Voting Rights Announcements Classification · 89% confidence The document is a press release announcing the results of the company’s Annual General Meeting held on May 19, 2026, listing the resolutions approved and referring to the vote tally. This matches the definition of a Declaration of Voting Results & Voting Rights Announcement (Code: DVA).
2026-05-20 French
Modalités de mise à disposition des documents préparatoires à l'AG
AGM Information Classification · 95% confidence The document is a press release announcing the upcoming Annual General Meeting (Assemblée Générale Mixte) of GenSight Biologics scheduled for May 19, 2026. It includes information about the meeting date, webcast access, a summary of operational highlights from 2025, and strategic priorities for 2026. There is no detailed financial report or comprehensive financial statements included. The document serves as an announcement and invitation to the AGM rather than the AGM materials or the full annual report itself. The length is under 5,000 characters and it primarily announces the AGM event and agenda. Therefore, the document fits the category of AGM Information (AGM-R).
2026-05-18 French
Terms of availability of the preparatory documents for the GM
AGM Information Classification · 95% confidence The document is a press release announcing the upcoming Combined General Meeting (CGM) of GenSight Biologics scheduled for May 19, 2026. It includes a summary of key operational developments in 2025 and priorities for 2026, but it does not contain detailed financial statements or comprehensive report data. The document also provides information on how to participate in the meeting and mentions that the CEO will present an overview during the meeting. The length of the document is 4259 characters, which is relatively short and consistent with an announcement rather than a full report. There is no indication that this is the actual AGM presentation material or the full annual report. Therefore, this document fits the category of AGM Information (AGM-R), as it relates to the Annual General Meeting and provides information about the meeting and its agenda.
2026-05-18 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 12% confidence The document is a press release announcing the publication of a scientific article (matching-adjusted indirect comparison) in a medical journal. It does not contain any financial statements, regulatory compliance details, management changes, dividends, or meeting materials. It is not a company report itself, nor an announcement of a financial or corporate report; it is simply a publicity announcement of an academic publication. No specific category (e.g., Annual Report, Interim Report, Earnings Release, Dividend Notice, etc.) applies. Therefore, we classify it into the fallback category for miscellaneous regulatory/other announcements: Regulatory Filings (RNS).
2026-05-11 French

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.